Play Live Radio
Next Up:
0:00
0:00
0:00 0:00
Available On Air Stations
Tell us how you use the radio, along with social media, smartphones, tablets, streaming and the web to stay connected to entertainment, news and updates from MTPR and other sources. Whether you use all these things or none, your response is helpful.

Eli Lilly says an experimental drug slows Alzheimer's worsening

A sign for Eli Lilly & Co. sits outside their corporate headquarters in Indianapolis on April 26, 2017. The company said Wednesday, May 3, 2023, that its experimental Alzheimer's drug appeared to slow worsening of the mind-robbing disease in a large study.
Darron Cummings
/
AP
A sign for Eli Lilly & Co. sits outside their corporate headquarters in Indianapolis on April 26, 2017. The company said Wednesday, May 3, 2023, that its experimental Alzheimer's drug appeared to slow worsening of the mind-robbing disease in a large study.

WASHINGTON — Eli Lilly and Co. said Wednesday its experimental Alzheimer's drug appeared to slow worsening of the mind-robbing disease in a large study.

In the 18-month trial, people in the early stages of Alzheimer's who received infusions of donanemab showed 35% less decline in thinking skills compared to those given a dummy drug, Lilly announced in a press release.

The drug is designed to target and clear away a sticky protein called beta-amyloid that builds up into brain-clogging plaques that are one hallmark of Alzheimer's.

A similar amyloid-targeting drug, Eisai and Biogen's Leqembi, recently hit the market with similar evidence that it could modestly slow Alzheimer's — and also some safety concerns, brain swelling or small brain bleeds.

Donanemab also comes with that risk. Lilly said in its study, the brain side effects caused the deaths of two participants and a third also died after a serious case.

The preliminary study results haven't been vetted by outside experts. Indianapolis-based Lilly plans to release more details at an international Alzheimer's meeting this summer and is seeking Food and Drug Administration approval of the drug.

Copyright 2023 NPR. To see more, visit https://www.npr.org.

Tags
The Associated Press
[Copyright 2024 NPR]
Become a sustaining member for as low as $5/month
Make an annual or one-time donation to support MTPR
Pay an existing pledge or update your payment information